Ph.1b/II study of buparlisib with docetaxel in squamous NSCLC patients

• Research type

  Research Study

• Full title

  A Phase Ib/II study of docetaxel with or without buparlisib as second line therapy for patients with advanced or metastatic squamous non-small cell lung cancer

• IRAS ID

  135154

• Contact name

  Rohit Lal

• Contact email

  Rohit.Lal@gstt.nhs.uk

• Sponsor organisation

  Novartis Pharma Services AG

• Eudract number

  2013-000833-11

• ISRCTN Number

  N/A

• REC name

  London - South East Research Ethics Committee

• REC reference

  13/LO/1154

• Date of REC Opinion

  14 Oct 2013

• REC opinion

  Further Information Favourable Opinion